SM08502 is a first-in-class CLK inhibitor being investigated in a Phase 1 clinical trial for subjects with advanced solid tumors.doi:10.1016/j.canlet.2019.09.009Betty Y. Tam aKevin Chiu bHeekyung Chung bCarine Bossard bJohn Duc Nguyen a...
Cirtuvivint (SM08502) is a potent and orally active CDC-like kinase (CLK) inhibitor. Cirtuvivint can be used for solid tumors research[1]. 体外研究 (In Vitro) Cirtuvivint (SM08502) inhibits serine and arginine rich splicing factor (SRSF) phosphorylation and disrupted spliceosome activity, ...